Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600516 | 0.86 | PTGS2 (0.52) | PTGS2NPC1LMNAPKMHTT | |
| SCHEMBL599638 | 0.84 | KDM4E (0.34) | PTGS2PKMALDH1A1 | |
| SCHEMBL602915 | 0.79 | PTGS2 (0.39) | PTGS2ALDH1A1PDE3BPDE3AP2RY12 | |
| SCHEMBL601768 | 0.73 | PTGS2 (0.35) | PTGS2PKMHTTALDH1A1 | |
| SCHEMBL3920674 | 0.68 | PTGS2 (0.62) | PTGS2NPC1LMNARAB9AALDH1A1 | |
| SCHEMBL599891 | 0.67 | PTGS2 (0.39) | PTGS2LMNAHTTALDH1A1PDE3B | |
| SCHEMBL11662106 | 0.66 | HDAC3 (0.54) | PTGS2LMNAPKMHTTRAB9A | |
| SCHEMBL9810752 | 0.65 | RAB9A (0.58) | PTGS2NPC1LMNAPKMHTT | |
| SCHEMBL18784399 | 0.65 | ALDH1A1 (0.54) | PTGS2LMNARAB9AALDH1A1 | |
| SCHEMBL18784610 | 0.65 | ALDH1A1 (0.54) | PTGS2LMNARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | PTGS2 347/4885NPC1 2692/4885LMNA 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.